-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Earlier, Theratechnologies Enters Definitive Agreement To Be Acquired By CB Biotechnology For $3.01 Per Share Plus Contingent Value Right

Benzinga·07/03/2025 06:16:40
Listen to the news
  • Offer of US$3.01 in cash plus one contingent value right for potential additional aggregate payments of up to US$1.19 per share
  • Upfront and total potential cash consideration represent respectively a 126% and 216% premium to Nasdaq closing price on date prior to announcement of Future Pak's initial non-binding proposal
  • Transaction with Future Pak represents culmination of sale process whereby Theratechnologies solicited interest from a number of potential counterparties
  • Board unanimously recommends that shareholders approve the transaction